Mark Thursz is professor of hepatology at Imperial College and consultant in hepatology at St Mary's Hospital, London. His clinical interests are in viral hepatitis, alcoholic liver disease and fatty liver disease. He is currently interested in developing programmes for treatment of chronic hepatitis B infection in resource poor settings to reduce the risk of hepatocellular carcinoma.
Professor Thursz' research interests are focussed on the natural history of viral hepatitis and fatty liver disease and the factors which determine chronic infection and progressive liver disease. He has a special interest in the genetic determinants of disease outcomes using genetic association and genome wide scanning to identify causative variants.
Professor Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial.
Professor Thursz is a former secretary of the British Association for Study of the Liver (BASL) and is currently vice-secretary of the European Association for Study of the Liver. In this role he has special responsibility for EU policy and advocacy in Brussels.
et al., 2023, Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis., Nat Commun, Vol:14
et al., 2023, Metabolic profile reflects stages of fibrosis in patients with non-alcoholic fatty liver disease, International Journal of Molecular Sciences, Vol:24, ISSN:1422-0067, Pages:1-12
et al., 2023, Cost-effectiveness of different monitoring strategies in a screening and treatment programme for hepatitis B in The Gambia, Journal of Global Health, Vol:13, ISSN:2047-2978, Pages:1-11
Whitfield JB, Seth D, Morgan TR, 2022, All-cause and liver-related mortality risk factors in excessive drinkers: Analysis of data from the UK biobank, Alcoholism-clinical and Experimental Research, Vol:46, ISSN:0145-6008, Pages:2245-2257
et al., 2022, Clinical and cost-effectiveness analysis of community-based screening strategies for non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus